Focus: Use of Gilead's HIV prevention shot rises, but US insurance gaps remain

Use of Gilead Sciences' Yeztugo, a twice-yearly injection to prevent HIV infection, has climbed since its June launch, but U.S. health providers say not all patients are interested in the new option and those who want to try it ​can face insurance coverage gaps.